A randomized <scp>DBPC</scp> trial to determine the optimal effective and safe dose of a <scp>SLIT</scp>‐birch pollen extract for the treatment of allergic rhinitis: results of a phase <scp>II</scp> study

Abstract

A multicentre trial evaluated the dose-response and tolerability of SB. All active treatment groups showed better responses than placebo for both primary and secondary parameters. The results indicate that, within the studied dose range, SB 40,000 AUN/ml is the most optimal effective and safe dose (ClinicalTrials.gov: NCT01639768).